CR Bard's CEO Discusses Q4 2011 Results - Earnings Call Transcript

CR Bard (BCR)

Q4 2011 Earnings Call

January 31, 2012 5:00 pm ET


Timothy M. Ring - Chairman, Chief Executive Officer and Chairman of Executive Committee

John H. Weiland - President, Chief Operating Officer and Director

Todd C. Schermerhorn - Chief Financial Officer and Senior Vice President

John A. DeFord - Senior Vice President of Science Technology & Clinical Affairs


Lawrence S. Keusch - Morgan Keegan & Company, Inc., Research Division

Brooks E. West - Piper Jaffray Companies, Research Division

Jonathan J. Palmer - Credit Agricole Securities (USA) Inc., Research Division

David R. Lewis - Morgan Stanley, Research Division

Matthew Taylor - Barclays Capital, Research Division

Michael Matson - Mizuho Securities USA Inc., Research Division

Michael N. Weinstein - JP Morgan Chase & Co, Research Division

Miroslava Minkova - Leerink Swann LLC, Research Division

Kristen M. Stewart - Deutsche Bank AG, Research Division

Topher Orr - Goldman Sachs Group Inc., Research Division

Joanne K. Wuensch - BMO Capital Markets U.S.

Robert A. Hopkins - BofA Merrill Lynch, Research Division

Jason Wittes - Caris & Company, Inc., Research Division

Matthew O'Brien - William Blair & Company L.L.C., Research Division

Anthony Petrone - Jefferies & Company, Inc., Research Division

Suraj Kalia - Rodman & Renshaw, LLC, Research Division

Gregory Hertz - Citigroup Inc, Research Division

Robert M. Goldman - CL King & Associates, Inc.

Jayson T. Bedford - Raymond James & Associates, Inc., Research Division



Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Fourth Quarter 2011 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand replay through the Bard website.

Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; and Todd C. Schermerhorn, Senior Vice President of Science Technology and Clinical Affairs; and Todd W. Garner, Vice President, Investor Relations.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts